EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice

Diana De Oliveira-Gomes, Parag H Joshi iD, Eric D Peterson iD, Anand Rohatgi iD, Amit Khera iD, Ann Marie Navar

Circulation · 02.07.2024 · 150 (1) · 62-79

DOI: 10.1161/circulationaha.124.068885 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation, erschienen am 02.07.2024. Verfasst von Diana De Oliveira-Gomes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (D.D.O.-G.), University of Texas Southwestern Medical Center, Dallas. Hauptthemen laut MEDLINE: Apolipoproteins B, Cholesterol, LDL. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in predicting atherosclerotic cardiovascular disease risk, apoB measurement has not become widely adopted into routine clinical practice. One barrier for use of apoB measurement is lack of consistent guidance for clinicians on how to interpret and apply apoB results in clinical context. Whereas guidelines have often provided clear low-density lipoprotein cholesterol targets or triggers to initiate treatment change, consistent targets for apoB are lacking. In this review, we synthesize existing data regarding the epidemiology of apoB by comparing guideline recommendations regarding use of apoB measurement, describing population percentiles of apoB relative to low-density lipoprotein cholesterol levels, summarizing studies of discordance between low-density lipoprotein cholesterol and apoB levels, and evaluating apoB levels in clinical trials of lipid-lowering therapy to guide potential treatment targets. We propose evidence-guided apoB thresholds for use in cholesterol management and clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoproteins BCholesterol, LDLHumansPractice Guidelines as TopicCardiovascular DiseasesBiomarkersAtherosclerosisApolipoprotein B-100

Stichwörter der Autor:innen

apolipoproteinscardiometabolic risk factorslipoproteinslipoproteins, LDL

Substanzen

Apolipoproteins BCholesterol, LDLBiomarkersAPOB protein, humanApolipoprotein B-100

Autor:innen und Institutionen

  • Department of Internal Medicine (D.D.O.-G.), University of Texas Southwestern Medical Center, Dallas.
  • Division of Cardiology (P.H.J., E.D.P., A.R., A.K., A.M.N.), University of Texas Southwestern Medical Center, Dallas.

ORCID-Profile: Parag H Joshi, Eric D Peterson, Anand Rohatgi, Amit Khera

Förderung

  • NHLBI NIH HHS

Zitieren

APA

De Oliveira-Gomes, D., Joshi, P. H., Peterson, E. D., Rohatgi, A., Khera, A., & Navar, A. M. (2024). Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation, 150(1), 62-79. https://doi.org/10.1161/circulationaha.124.068885

Vancouver

De Oliveira-Gomes D, Joshi PH, Peterson ED, Rohatgi A, Khera A, Navar AM. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation. 2024;150(1):62-79. doi:10.1161/circulationaha.124.068885

BibTeX
@article{DeOliveiraGomes2024,
  author = {De Oliveira-Gomes, Diana and Joshi, Parag H and Peterson, Eric D and Rohatgi, Anand and Khera, Amit and Navar, Ann Marie},
  title = {Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice},
  journal = {Circulation},
  year = {2024},
  volume = {150},
  number = {1},
  pages = {62--79},
  doi = {10.1161/circulationaha.124.068885}
}
Kostenlos starten →